Pharmaceutical Technology

JUNE 16, 2023

Merck ( MSD ) has announced updated results with Keytruda (pembrolizumab) in the Phase III Keynote-811 trial, which opens up the possibility of changing the checkpoint inhibitor’s label in HER2-positive gastric or GEJ adenocarcinoma so it’s based on the tumour’s PD-L1 biomarker status. It showed promising event-free survival (EFS) of 62.4%

Chemotherapy 52

Chemotherapy Labelling FDA Communication 52

Pharmaceutical Technology

SEPTEMBER 23, 2022

The current standard of care for many cancers is cisplatin chemotherapy or platinum therapy. These open-label, randomized clinical trials were done in patients under 18 years of age. More than double the volume of Fennec’s shares were traded on the day of the approval news in comparison to 19 September. Pedmark clinical trials.

FDA 52

FDA Communication Chemotherapy Labelling 52

The Checkup by Singlecare

NOVEMBER 21, 2024

Instead, the product manufacturer is responsible for ensuring that their product is safe and that the product label claims are truthful. However, Mount Sinai notes that echinacea may reduce the effectiveness of immunosuppressant medications, such as drugs used for organ transplants or chemotherapy. Its drug interaction risk is low.

FDA 52

FDA Labelling Chemotherapy Dosage 52

Pharmacy Times

JUNE 23, 2025

Datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc) received FDA approval for treatment of adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.

FDA 86

FDA Compounding Pharmacies Chemotherapy Immunization 86

Pharmacy Times

JUNE 20, 2025

There are too many drug approvals, label updates, and new data published for even the most skilled and experienced oncology pharmacist to keep up with, let alone those still building their baseline knowledge. Oncology pharmacy practice changes at a rapid pace. Fifteen years ago, pharmacists could learn oncology on the job.

Compounding 107

Compounding Compounding Pharmacies Patient Care Immunization 107

Pharmacy Times

JUNE 11, 2025

Its efficacy was evaluated in the 2 multicenter, single-arm open-label phase 2 clinical trials TRUST-I (NCT04395677) 3 and TRUST-II (NCT04919811). Additionally, patients may have received prior chemotherapy for advanced disease. 1-4 TRUST-I findings showed that taletrectinib achieved a cORR of about 90% in patients who were TKI-naïve.

FDA 73

FDA Compounding Pharmacies Immunization Hospitals 73

European Pharmaceutical Review

AUGUST 17, 2022

The approval of Advanced Accelerator Applications (AAA)’s Pluvicto is based on the alternate primary endpoint results from the randomised, open-label, international, multi-centre, Phase III VISION trial, where patients with progressive PSMA positive mCRPC treated with at least one AR pathway inhibitor and one or two taxane regimens.

Chemotherapy 122

Chemotherapy Compounding Labelling 122

Pharmacy Times

JUNE 9, 2025

2 However, Dalton noted that some procedures can change once a treatment is FDA-approved, with complications from Risk Evaluation and Mitigation Strategy programs as well as the occasional surprise on an FDA label. But doing so requires a new kind of expertise that spans science, strategy, and systems thinking. Subscribe Now!

Compounding Pharmacies 56

Compounding Pharmacies FDA Hospitals Immunization 56

Pharmacy Times

JUNE 23, 2025

Additionally, ANDA submissions should extrapolate the RLD safety and effectiveness data for drugs with the same active ingredients, dosage forms, strengths, routes, and labeling. In the 505(j) ANDA approval pathway, on the other hand, submissions can be multisource generic drugs; however, this pathway requires bioequivalence to the RLD.

FDA 65

FDA Compounding Pharmacies Dosage Hospitals 65

pharmaphorum

APRIL 1, 2021

The FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, building on a first approval last year. In the trial, 8% of patients dropped out because of adverse events and 2.8% quit because of an infection.

Adverse Reactions 59

Adverse Reactions Labelling Chemotherapy FDA 59

Hospital Pharmacy Europe

SEPTEMBER 7, 2023

The use of adjunctive alectinib reduced disease recurrence in the early setting for people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) compared to platinum-based chemotherapy, its manufacturer Roche has announced. The OS data were immature at the time of the interim analysis.

Chemotherapy 52

Chemotherapy Labelling Hospitals 52

pharmaphorum

AUGUST 2, 2021

Tibsovo (ivosidenib) was already on the market when Servier made its play for Agios’ assets, having secured US approvals as a treatment for relapsed or refractory IDH1-mutant AML in 2018 and as a monotherapy for newly diagnosed IDH1-mutant AML in patients aged over 75 or unable to take chemotherapy in 2019.

Chemotherapy 59

Chemotherapy Labelling 59

pharmaphorum

FEBRUARY 15, 2022

Armed with new clinical trial results, Amgen is expanding studies of its KRAS inhibitor Lumakras in pancreatic cancer, as it tries to extend the label for the first-in-class drug beyond its current use in non-small cell lung cancer (NSCLC).

Labelling 52

Labelling Chemotherapy FDA 52

Pharmaceutical Technology

DECEMBER 11, 2022

For young patients with MCL, the standard of care (SOC) is a rituximab-based chemotherapy regimen such as R-CHOP/DHAP, followed by an autologous stem cell transplant (ASCT). The addition of Imbruvica to the standard rituximab regimen did not lead to an increase in Grade 5 events, and Grade 3 and higher events increased only slightly.

Chemotherapy 52

Chemotherapy Labelling 52

The Checkup by Singlecare

MARCH 21, 2023

There are other options available to treat pain that does not improve with hydrocodone-acetaminophen or in patients who experience adverse events. Cymbalta is a non-opioid medication and was actually originally labeled as an antidepressant , more specifically a serotonin /norepinephrine reuptake inhibitor (SNRI).

Dosage 52

Dosage Controlled Substances Labelling Chemotherapy 52

The Checkup by Singlecare

MAY 8, 2023

Cymbalta is a non-opioid medication and is labeled as an antidepressant, more specifically a serotonin/norepinephrine reuptake inhibitor (SNRI). NSAID use is associated with an increased risk of cardiovascular events’ , including the development of high blood pressure.

Controlled Substances 52

Controlled Substances Dosage Labelling FDA 52

pharmaphorum

DECEMBER 14, 2022

At ASH, the E1910 clinical trial generated results could unlock a new patient population for Blincyto, after it was shown to improve overall survival in patients with no measurable residual disease (MRD) after induction chemotherapy for B-ALL. At the moment, Blincyto is approved to treat patients with MRD after induction treatment.

Mayo Clinic 52

Mayo Clinic Chemotherapy Labelling Hospitals 52

Pharmaceutical Technology

FEBRUARY 27, 2023

To identify key events from late December to late January, this news service collated manufacturing contract-related data from PharmSource reports, and news from GlobalData’s Pharma Intelligence Center, to identify participants that are likely to experience an impact following the news.

Packaging 52

Packaging Chemotherapy FDA Communication 52

Pharmacy Times

JUNE 9, 2025

The CheckMate 816 trial showed a high pathological complete response rate without increased adverse events, supporting nivolumab as a standard treatment. SHOW MORE Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option.

Chemotherapy 65

Chemotherapy Compounding Pharmacies Immunization Compounding 65

The Thyroid Pharmacist

SEPTEMBER 1, 2023

They include anesthetics, antacids, anti-anxiety medications, antibiotics, antidepressants, antifungals, cholesterol-lowering medications, anti-malarial medications, chemotherapy, appetite suppressants, arthritis medications, psychotropics, and steroids. References [1] Ghosh A, Mukherjee K, Ghosh S, Saha B. 2012;39(7):2881-2915.

Adverse Reactions 116

Adverse Reactions Compounding Chemotherapy Labelling 116

Pharmacy Times

JUNE 27, 2025

Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. Treatment-related adverse events (AEs) included nausea (77.8% vs 10.8%, respectively), and major bleeding events (2.4% ORRs were 94.4% in the TN cohort (95% CI, 72.7%-99.9%) 99.9%) and 85.0% in the R/R cohort (95% CI, 62.1%-96.8%).

FDA 56

FDA Compounding Pharmacies Immunization Chemotherapy 56

Hospital Pharmacy Europe

MARCH 17, 2025

A total of 1,074 patients underwent randomisation in a 2:2:1 ratio to receive amivantamablazertinib (open-label), osimertinib (blinded), or lazertinib (blinded, to assess the contribution of treatment components). Predominant adverse events were EGFR-related toxic effects. to 0.85; P<0.001).

Chemotherapy 52

Chemotherapy Labelling Hospitals 52

The Thyroid Pharmacist

NOVEMBER 29, 2024

Instead, it goes into emergency mode, pumping your body full of adrenaline to prepare it to survive what your body perceives to be a life-threatening event. P.S. Be sure to sign up for my weekly newsletter to get a free chapter of my first book, recipes, a Thyroid Diet start guide, and notifications about upcoming events.

Health and Personal Care Stores 98

Health and Personal Care Stores Immunization Medical Schools Chemotherapy 98